Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Delft – page 7

1 232 clinical trials in Delft, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Delft at a glance
1 232
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 232 trials in Delft

Open in trial search

Infectious pleural effusion

Recruiting

Intrapleural Alteplase and Dornase Alfa versus VATS for Patients with Pleural Empyema (Parapneumonic Pleural Infection)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Amsterdam UMC Stichting

Cholangitis sclerosing

Recruiting

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Huntington's disease

Recruiting

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Myasthenia gravis

Recruiting

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Hypereosinophilic syndrome+1

Recruiting

Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Hepatic cirrhosis

Recruiting

Low‑dose human serum albumin versus standard dose during large‑volume paracentesis in patients with liver cirrhosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Amsterdam UMC Stichting

Duchenne muscular dystrophy+1

Recruiting

Long‑Term Safety and Efficacy Study of ENTR‑601‑45 and ENTR‑601‑44 in Participants with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-44
  • Sponsor:Entrada Therapeutics Inc.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Delft

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular disease management and prevention, including studies of novel treatments for atherosclerotic cardiovascular disease and innovative therapies targeting lipoprotein reduction.

  • Lipid Management Studies
  • Cardiovascular Risk Prevention
  • Major Adverse Cardiac Events

Research exploring both established and experimental treatments to reduce cardiovascular complications and improve patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, with significant focus on prostate cancer, breast cancer, and blood cancers including chronic lymphocytic leukemia.

  • Advanced Imaging Techniques
  • Targeted Therapies
  • Treatment Combinations

Innovative approaches combining established treatments with novel therapeutic agents to enhance treatment effectiveness.

03 Women's Health

Studies addressing various aspects of women's health, including infertility treatments and management of uterine fibroids.

  • Reproductive Health
  • Gynecological Conditions
  • Quality of Life Studies

Research comparing different treatment modalities and their impact on patient outcomes and quality of life.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.